Gregory Locke

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

14h-index550citations38works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(18), Peptidase Inhibition and Analysis(5), Metabolism and Genetic Disorders(4), Neutrophil, Myeloperoxidase and Oxidative Mechanisms(4), Neuroblastoma Research and Treatments(4)

Publications38 total

Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408
Journal of Medicinal Chemistry·2025
Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S6 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Cancer Immunology Research·2025· 6 citedOpen Access
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
Journal of Medicinal Chemistry·2024· 6 cited
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity
Science Translational Medicine·2023· 23 cited
Discovery of Non-Nucleotide Small-Molecule STING Agonists <i>via</i> Chemotype Hybridization
Journal of Medicinal Chemistry·2022· 31 citedOpen Access
Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling
Methods in enzymology on CD-ROM/Methods in enzymology·2022· 6 cited
Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO)
Bioorganic & Medicinal Chemistry Letters·2021· 15 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Joelle M. Onorato(20), Michael Wichroski(17), John N. Feder(16), Shana Posy(16), Si-Qi Liu(16), Louis Chupak(16), Hongchen Qiu(16), Dana Banas(16), Abigail E. Witt(16), Huilin Qi(16), Christopher M. Barbieri(16), Joseph L. Benci(15), Ryan L. Powles(15), Jessica Wong(15), Erica Cook(15), Denise C. Grünenfelder(15), Emma Lees(15), Lauren M. Zasadil(14), Patrick C. Gedeon(14), Kendall J. Condon(14)